Full-Time

Neurology Asset/Indication Lead

Health Economics and Value Assessment

Updated on 9/3/2026

Deadline 9/25/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$178.5k - $257.8k/yr

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

Hybrid

Three days in-office per week required.

Master's, PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Electronic Health Records (EHR)
Biostatistics
Data Analysis

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • An advanced degree (PhD, MD, MS, MPH, or PharmD) in a scientific discipline is required.
  • At least 5 years of experience in health economics, outcomes research, or a related field is required.
  • Experience with US product launches and US payer evidence requirements and value demonstration is required.
  • Understanding of the US healthcare system and payer dynamics, with the ability to translate evidence into strategic insights, is required.
  • Demonstrated experience applying economic modeling, observational research, evidence synthesis, and Clinical Outcomes Assessment development to research projects is required.
  • Proficiency in evidence-based medicine, clinical research methodology, health economic modeling, and patient-reported outcomes is required.
  • Experience translating Target Value Propositions and market access strategies into evidence hypotheses, requirements, and generation plans is required.
  • Experience supporting market access and reimbursement through HEVA evidence, including value tools, evidence summaries, and AMCP dossier contributions, is required.
  • Working knowledge of US evidence dissemination, including HCEI/PIE, reactive and proactive dissemination, and CFL, is required.
  • An established track record of scientific or methods publications in peer-reviewed journals is required.
  • Knowledge of global Health Technology Assessment processes and guidelines is required.
  • The ability to partner effectively with commercial, medical affairs, clinical development, and market access colleagues is required.
  • Compliance with relevant internal standard operating procedures and external laws and regulations is required.
  • Understanding of neurology disease pathophysiology, drug mechanisms of action including biologics and targeted therapies, health economic modeling, clinical development principles, epidemiology, biostatistics, Clinical Outcomes Assessment development, systematic literature reviews, and network meta-analyses is required.
  • Working proficiency with Health Economics and Outcomes Research digital tools and data platforms is required.
  • Familiarity with US real-world data sources, including claims databases and electronic health records, and their application to neurology outcomes research is required.
  • Experience with statistical analysis methods relevant to Health Economics and Outcomes Research is required.
  • Foundational knowledge of artificial intelligence, digital tools, data analytics platforms, and digital research tools relevant to health economics is required.
  • The ability to present complex scientific and strategic content to senior management and cross-functional audiences is required.
  • The ability to work independently and manage multiple priorities in a fast-paced, matrixed environment is required.
  • Understanding of the pharmaceutical industry's legal and regulatory environment and demonstrated integrity in compliance matters is required.
Responsibilities
  • Develop and implement US payer-specific HEVA strategy for launch and lifecycle management of the neurology pipeline.
  • Execute HEVA tactics that support commercial objectives and market access goals compliantly and efficiently.
  • Execute comprehensive US HEVA tactics for the neurology portfolio and align them with broader portfolio objectives.
  • Translate HEVA insights into actionable business strategies for the US neurology market.
  • Generate and disseminate evidence addressing US payer evidence requirements and value demonstration.
  • Develop US research agendas and ensure evidence priorities are reflected in Integrated Evidence Generation Plans.
  • Set HEOR evidence-generation priorities for assigned neurology indications and translate Target Value Propositions and US market access strategies into evidence hypotheses, requirements, and generation plans.
  • Build relationships with commercial, medical affairs, clinical development, and market access teams to align pricing and access decisions with demonstrated portfolio value.
  • Align with the Global HEVA team on US insights, evidence generation, modeling, and evidence synthesis activities.
  • Communicate health economics concepts and strategic recommendations to cross-functional stakeholders and senior leadership.
  • Influence business decisions through data-driven insights and strategic HEVA recommendations.
  • Contribute to clinical development plans that support differentiation and US payer value demonstration.
  • Contribute to US launch-readiness planning and serve as the HEVA subject matter expert in governance forums and brand team meetings.
  • Lead the design and execution of HEOR activities across multiple neurology indications and development stages.
  • Oversee the design, execution, and publication of HEOR studies, including economic modeling, database analysis, observational research, Clinical Outcomes Assessment development and validation, systematic literature reviews, evidence synthesis, and AMCP dossier development.
  • Apply economic modeling and Clinical Outcomes Assessments to generate evidence for US payers, Health Technology Assessment bodies, and other decision-makers.
  • Apply observational data analysis, post hoc clinical-trial analysis, meta-analysis, and indirect treatment comparisons to demonstrate pipeline asset value.
  • Execute HEVA tactics to disseminate and apply HEOR evidence with US stakeholders.
  • Use data-driven decision-making frameworks to prioritize evidence gaps and research investments.
  • Contribute to real-world evidence strategies supporting product lifecycle management.
  • Represent Sanofi at scientific conferences and industry forums, including abstract development and presentation delivery.
  • Develop research relationships with US payers and other decision-makers to improve HEOR impact and build advocates for Sanofi data.
  • Collaborate with external research partners and key opinion leaders on HEVA strategy and tactical plans.
  • Engage with external evidence bodies, including ICER, PDAB, and IRA, to shape evidence-generation and value-demonstration strategies.
  • Build and sustain working relationships with patient advocacy organizations in neurology.
  • Manage HEVA research investments and vendor relationships for assigned neurology indications.
  • Operate independently with minimal supervision and exercise scientific and strategic judgment in designing and prioritizing HEOR activities.
  • Mentor junior HEVA team members on neurology HEOR methods, US payer dynamics, and evidence-generation practices.
  • Develop peer relationships across HEVA and cross-functional teams to establish HEVA as a recognized center of excellence in neurology HEOR.
  • Anticipate communication needs and address issues with timely action.
  • Contribute to continuous improvement of HEVA processes, tools, and capabilities.
  • Apply global and US-specific Health Technology Assessment processes and guidelines.
  • Ensure HEOR activities comply with internal standard operating procedures and external laws and regulations.
  • Stay current with US payer policies, formulary management practices, and outcomes-based contracting frameworks.
  • Apply HEOR digital tools and data platforms to improve evidence-generation efficiency and quality.
  • Use digital and artificial-intelligence-enabled solutions for systematic literature reviews, evidence synthesis, and economic modeling.
  • Apply real-world data analytics and advanced data platforms to neurology evidence generation.
  • Maintain foundational knowledge of emerging digital methodologies and champion their adoption within the neurology HEVA team.
Desired Qualifications
  • Experience with Health Technology Assessment submissions is preferred.
  • Neurology experience and familiarity with the competitive landscape in neurological diseases are strongly preferred.
  • Expertise or prior launch or peri-launch experience in neurodegenerative diseases, movement disorders, or neuromuscular diseases is preferred.
  • Experience supporting US payer advisory boards, formulary submissions, or outcomes-based contracting negotiations is preferred.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.